ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Perspectives on Manufacturing of High-Quality Cell Therapies.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Predicting ACI Outcomes with GMP In-Process Control Kinetic Metrics: Initial Chondrocyte Yield and Population Doubling Time as Prognostic Clinical Biomarkers.Life (Basel, Switzerland) · 2026Article
- Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives.European journal of medical research · 2024Review
- Improving access to gene therapy for rare diseases.Disease models & mechanisms · 2024Article
- Engineering mesenchymal stem cells for premature ovarian failure: overcoming challenges and innovating therapeutic strategies.Theranostics · 2024Review
- Mesenchymal stromal cells for bone trauma, defects, and disease: Considerations for manufacturing, clinical translation, and effective treatments.Bone reports · 2023Article
- Phenotyping senescent mesenchymal stromal cells using AI image translation.Current research in biotechnology · 2023Article
- Functional imaging with dynamic quantitative oblique back-illumination microscopy.Journal of biomedical optics · 2022Article
- Single-cell sorting based on secreted products for functionally defined cell therapies.Microsystems & nanoengineering · 2022Review
- Human limbal epithelial stem cell regulation, bioengineering and function.Progress in retinal and eye research · 2021Review
- Promises and challenges of adoptive T-cell therapies for solid tumours.British journal of cancer · 2021Review
- Investigating heterogeneities of live mesenchymal stromal cells using AI-based label-free imaging.Scientific reports · 2021Article
- Integrating United States Biomanufacturing Across Vaccines and Therapeutics.NAM perspectives · 2021Article
- Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway.Science advances · 2020Article
- Mass Spectrometry Advances and Perspectives for the Characterization of Emerging Adoptive Cell Therapies.Molecules (Basel, Switzerland) · 2020Review
- Article
- Development and validation of broad-spectrum magnetic particle labelling processes for cell therapy manufacturing.Stem cell research & therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.